Treatment of HCV prior to liver transplantation to prevent HCV recurrence - Wise or wasteful?

Liver International

Volumn 35, Issue 1, 2015, Pages 9-11

  Gallegos Orozco, Juan F ^a   Charlton, Michael R ^b  

^a UNIVERSITY OF UTAH   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; DASABUVIR; GRAZOPREVIR; GS 5816; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN; LEDIPASVIR; MK 8742; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VIRUS RNA; URIDINE PHOSPHATE;

ANTIVIRAL THERAPY; ASCITES; DECOMPENSATED LIVER CIRRHOSIS; EDITORIAL; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PEROPERATIVE CARE; PORTAL HYPERTENSION; PREOPERATIVE TREATMENT; RECURRENT INFECTION; REOPERATION; TREATMENT DURATION; VIRUS LOAD; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; ORAL DRUG ADMINISTRATION; PROCEDURES; RECURRENT DISEASE;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; RIBAVIRIN; URIDINE MONOPHOSPHATE;

EID: 84920972539     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12742     Document Type: Editorial

References (12)

1. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137: 1680-6.
2. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32(4 Pt 1): 852-8.
3. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 1003-19.
4. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012; 26: 531-48.
5. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
6. Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 2014; 60(Suppl): S28.
7. Terrault N, Satapathy S, Therapondos G, et al. Prevention of HCV Recurrence with Peri-Transplant Hepatitis C immune globulin combined with pre-transplant antiviral therapy. Hepatology. 2014; 60 (Suppl) 206 A.
8. Bzowej N, Nelson DR, Terrault NA, et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-38.
9. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2014; 147: 1189-444.
10. Forns X, Fontana RJ, Moonka D, et al. Initial evaluation of the sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation. Hepatology 2013; 58(Suppl): 732A.
11. Kwo PY, Mantry PS, Coakley E, et al. An Interferon-free Antiviral Regimen for HCV after Liver Transplantation.N Engl J Med. 2014; [Epub ahead of print].
12. Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with posttransplant recurrence: preliminary results of a prospective, multicenter study. Hepatology. 2014; 60 (Suppl) 200 A.